Nanomedicine and nano delivery systems are a relatively new but rapidly developing science where materials in the nanoscale range are employed to serve as means of diagnostic tools or to deliver therapeutic agents to specific targeted sites in a controlled manner Nanotechnology offers multiple benefits in treating chronic human diseases by site-specific, and target-oriented delivery of precise medicines Recently, there are a number of outstanding applications of the nanomedicine (chemotherapeutic agents, biological agents, immunotherapeutic agents etc) in the treatment of various diseases The current review, presents an updated summary of recent advances in the field of nanomedicines and nano based drug delivery systems through comprehensive scrutiny of the discovery and application of nanomaterials in improving both the efficacy of novel and old drugs (eg, natural products) and selective diagnosis through disease marker molecules The opportunities and challenges of nanomedicines in drug delivery from synthetic/natural sources to their clinical applications are also discussed In addition, we have included information regarding the trends and perspectives in nanomedicine area

/pdf/nano-based-drug-delivery-systems-recent-developments-and-2xpm2mog5c.pdf

Nano based drug delivery systems: recent developments and future prospects

In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half-life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real-time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

Polysaccharides-based nanoparticles as drug delivery systems

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.

https://digital.csic.es/bitstream/10261/134282/5/ADVANCED%20TARGETED.pdf

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Hydrophobic modifications of cationic polymers for gene delivery

In this study, novel nanoparticles were prepared by polyelectrolyte complexation between heparin and chitosan on simple and mild conditions. The size, polydispersity, zeta potential, and morphology of the nanoparticles were characterized. Entrapment studies of the nanoparticles were conducted using bovine serum albumin (BSA) as a model protein. Specifically, the effects of the pH value of chitosan solution, chitosan molecular weight (MW), chitosan concentration, heparin concentration, and BSA concentration on the nanoparticle size, the nanoparticle yield, and BSA entrapment were studied in detail. We found that, the size and the yield of the nanoparticles were affected by the above factors. The nanoparticle yield played a crucial role in BSA entrapment, namely, more nanoparticles could encapsulate more BSA. At length, suitably high pH value of chitosan solution, moderate chitosan MW, increasing both heparin concentration and chitosan concentration at an optimal concentration ratio favored more nanoparticles formed and consequently a higher BSA entrapment efficiency.

Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation.

In this study, carboxymethyl chitosan (CMC) hydrogel beads were prepared by crosslinking with Ca2+. The pH-sensitive characteristics of the beads were investigated by simulating gastrointestinal pH conditions. As a potential protein drug delivery system, the beads were loaded with a model protein (bovine serum albumin, BSA). To improve the entrapment efficiency of BSA, the beads were further coated with a chitosan/CMC polyelectrolyte complex (PEC) membrane by extruding a CMC/BSA solution into a CaCl2/chitosan gelation medium. Finally, the release studies of BSA-loaded beads were conducted. We found that, the maximum swelling ratios of the beads at pH 7.4 (17–21) were much higher than those at pH 1.2 (2–2.5). Higher entrapment efficiency (73.2%) was achieved in the chitosan-coated calcium-CMC beads, compared with that (44.4%) in the bare calcium-CMC beads. The PEC membrane limited the BSA release, while the final disintegration of beads at pH 7.4 still leaded to a full BSA release. Therefore, the chitosan-coated calcium-CMC hydrogel beads with higher entrapment efficiency and proper protein release properties were a promising protein drug carrier for the site-specific release in the intestine. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 103: 3164–3168, 2007

Calcium‐carboxymethyl chitosan hydrogel beads for protein drug delivery system

To combine the individual advantages of synthetic and natural polymers, poly(L-lactic acid) (PLLA)-chitosan hybrid scaffolds were fabricated. PLLA sponges were prepared by particulate-leaching, and then PLLA-chitosan hybrid scaffolds were obtained by dipping the PLLA sponges in chitosan solution and subsequently freeze-drying. Physicochemical properties of the scaffolds were characterized by scanning electron microscopy (SEM), water uptake test, and mechanical strength measurement. Moreover, cell adhesion, cell proliferation, and cell viability on the scaffolds were evaluated through osteoblast-like cell culture. The experimental results indicated that, PLLA sponges exhibited macroporous structure and the interconnected microporous structure of chitosan was formed within the macropores of PLLA sponges. The incorporation of chitosan reinforced PLLA sponges in dependence on chitosan content. The hybrid scaffolds had higher water uptake ability compared with PLLA sponges. Particularly, the hybrid scaffolds exhibited excellent cell attachment efficiency, cell proliferation, and cell viability. This study suggests that the hybrid scaffolds obtain good mechanical strength from PLLA and excellent cell compatibility from chitosan.

Zonghua Liu

Papers

Polysaccharides-based nanoparticles as drug delivery systems

Hydrophobic modifications of cationic polymers for gene delivery

Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation.

Calcium‐carboxymethyl chitosan hydrogel beads for protein drug delivery system

Fabrication and characterization of PLLA-chitosan hybrid scaffolds with improved cell compatibility.